Skába, Richard* Dotaz Zobrazit nápovědu

229 záznamů v Medvik

Článek

Influence of anesthesia on the results of intraoperative diagnostic electromyostimulation in patients with anorectal malformation

Journal of pediatric surgery. 2011 ; 46 (11) : 2135-9.

J Pediatr Surg
ISSN 1531-5037
Medvik
Zdroj

BACKGROUND AND PURPOSE: Stimulation electromyography (sEMG) is useful in identifying the sphincter muscle (M) in patients with anorectal malformations (ARMs). This study evaluates the effect of anesthetic agents and M relaxants on sEMG findings. MATERIALS AND METHODS: Seventeen infants (10 boys and 7 girls) with a mean age of 6.3 months and mean body weight of 6.7 kg were included in a prospective randomized study. Anesthesia was induced by sevoflurane and opioids, and an epidural catheter was inserted caudally. Stimulation electromyography of levator ani M using 14 mA current was used, and latency and amplitude of the evoked compound M action potential (CMAP) were recorded. Patients were randomized into 2 groups. Group A received a local anesthetic epidurally, and sEMG was performed. Administration of the M relaxant and measurement of M response followed. In group B drug administration, sEMG and response measurement were performed after administration of M relaxant. RESULTS: Baseline CMAP was recorded in all patients. Average latency was 4.1 milliseconds, and average amplitude was 0.43 mV. In group A, the average latency was 4.0 milliseconds, and average amplitude was 0.65 mV. After administration of the M relaxant, the CMAP disappeared. In group B, no CMAP was observed immediately after administration of the M relaxant. CONCLUSION: Administration of the inhalational anesthetic, opioids, and local anesthetic did not influence the M response of M fibers in the levator ani M on sEMG and enables its localization during ARM reconstruction. Nondepolarizing M relaxation completely abolished the response. If M relaxant is necessary, cisatracurium is used. The most suitable method of anesthesia for ARM surgery appears to be inhalational anesthesia supplemented by opioids and epidural analgesia.

Článek

Profesor Richard Škába novým Rytířem českého lékařského stavu

Tempus medicorum. 2023 ; 32 (4) : 3-4.

ISSN 1214-7524
Medvik
Zdroj

MeSH
chirurgie MeSH
odměny a ceny * MeSH
Publikační typ
biografie MeSH

O autorovi
Škába, Richard, 1949- Autorita

Článek

Člověk může být k dobru i přinucen : říká Prof. MUDr. Richard Škába, CSc., předseda Čestné rady ČLK

Škába, Richard, 1949-
Autor Autorita

Tempus medicorum. 2007 ; 16 (2) : 20-21.

ISSN 1214-7524
Medvik
Zdroj

MeSH
chirurgie MeSH
dítě MeSH
pediatrie MeSH
posudkové řízení ve zdravotní péči MeSH
společnosti lékařské organizace a řízení zákonodárství a právo MeSH
zaměstnanci - disciplína MeSH
Check Tag
dítě MeSH
Publikační typ
rozhovory MeSH

Článek

Dendritic cell-based immunotherapy induces transient clinical response in advanced rat fibrosarcoma - comparison with preventive anti-tumour vaccination

Folia biologica (Praha). 2009 ; 55 (4) : 119-125.

ISSN 0015-5500
Medvik
Zdroj

In this study we present the models of preventive and therapeutic vaccination of sarcoma-bearing rats with dendritic cells that present tumour antigens from killed tumour cells. We present the characteristics of dendritic cell-based vaccine and its capacity to induce anti-tumour immune response both in vitro and in vivo. We show that preventive vaccination efficiently prevents tumour growth. On the other hand, vaccination of rats with established tumours did not lead to eradication of the tumours. Despite the induction of a vigorous immune response after administration of dendritic cell-based vaccine and transient decrease in tumour progression, tumours eventually resumed their growth and animals vaccinated with dendritic cells succumbed to cancer. In both settings, preventive and therapeutic, dendritic cell-based vaccination induced a vigorous tumour-specific T-cell response. These results argue for the timing of cancer immunotherapy to the stages of low tumour load. Immunotherapy initiated at the stage of minimal residual disease, after reduction of tumour load by other modalities, will have much better chance to offer a clinical benefit to cancer patients than the immunotherapy at the stage of metastatic disease.